Back to results
US 2023/0414538 A1Published application
Dosage forms and methods for enantiomerically enriched or pure bupropion
AssigneeAxsome Therapeutics, Inc.
InventorHerriot Tabuteau
Life of this patent
Estimating the term…
Abstract
This disclosure relates to dosage forms containing an enantiomerically enriched or pure bupropion such as enantiomeric excess of (S)-bupropion, enantiomerically enriched (S)-bupropion, or enantiomerically pure (S)-bupropion and methods of using these dosage forms. These dosage forms may be administered to human beings in a reduced amount as compared to the amount of racemic bupropion that would be administered in the same situation.
Claims19
A method of treating attention deficit/hyperactivity disorder, comprising:
- orally administering a daily dose of an (S)-bupropion to a human being in need thereof which is about 120 mg to about 210 mg, wherein the (S)-bupropion is not deuterium-enriched;
- wherein the (S)-bupropion is at least 95% enantiomerically pure, and no other bupropion is orally administered with the daily dose of the (S)-bupropion;
- wherein the (S)-bupropion is in a dosage form, and wherein the dosage form contains no dextromethorphan, or contains less than 0.1% of dextromethorphan;
- and
- wherein the (S)-bupropion is orally administered once or twice daily.
2 more elements
Dependencies are inferred from the claim text.